José Luis López Estebaranz

Prof. José Luis López Estebaranz

orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2016 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
PDF file
ANA. Nast
A. Nast
BDB. Dréno
B. Dréno
VBV. Bettoli
V. Bettoli
ZMZ. Bukvic Mokos
Z. Bukvic Mokos
KDK. Degitz
K. Degitz
HGH. Gollnick
H. Gollnick

22 February 2012 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
PDF file
ANA. Nast
A. Nast
BDB. Dréno
B. Dréno
VBV. Bettoli
V. Bettoli
KDK. Degitz
K. Degitz
RER. Erdmann
R. Erdmann
HGH. Gollnick
H. Gollnick
Click on the article title to read more.

1 February 2018 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
DTDiane M. Thiboutot
Diane M. Thiboutot
BDBrigitte Dréno
Brigitte Dréno
AAAbdullah Abanmi
Abdullah Abanmi
AAAndrew F. Alexis
Andrew F. Alexis
EAElena Araviiskaia
Elena Araviiskaia
LXLeihong Flora Xiang
Leihong Flora Xiang

1 April 2012 in Archives of Dermatology
Verified
Journal Article
Open access
PDF file
GCGregorio Carretero
Gregorio Carretero
IGIgnacio Garcia-Doval
Ignacio Garcia-Doval
FVFrancisco Vanaclocha
Francisco Vanaclocha
CFCarlos Ferrandiz
Carlos Ferrandiz
EDEsteban Daudén
Esteban Daudén
CCCristina Carazo
Cristina Carazo
Research from JAMA Dermatology — Risk of Serious Adverse Events Associated With Biologic and Nonbiologic Psoriasis Systemic Therapy — Patients Ineligible vs Eligible for Randomized Controlled Trials

10 January 2013 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
BDB. Dréno
B. Dréno
ALA. Layton
A. Layton
Christos C. ZouboulisChristos C. Zouboulis
Christos C. Zouboulis
JEJosé Luis López Estebaranz
José Luis López Estebaranz
AZA. Zalewska‐Janowska
A. Zalewska‐Janowska
JHJ.C. Harper
J.C. Harper

14 May 2016 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
PDF file
HGH.P. Gollnick
H.P. Gollnick
VBV. Bettoli
V. Bettoli
JLJ. Lambert
J. Lambert
EAE. Araviiskaia
E. Araviiskaia
IBI. Binic
I. Binic
BDB. Dréno
B. Dréno
Background: Many current guidelines provide detailed evidence‐based recommendations for acne treatment.Objective: To create consensus‐based, simple, easy‐to‐use algorithms for clinical acne treatment in daily office‐based practice and to provide checklists to assist in determining why a patient may not have responded to treatment and what action to take.Methods: Existing treatment guidelines and consensus papers were reviewed. The information in them was extracted and simplified according to daily clinical practice needs using a consensus‐based approach and based on the authors' clinical expertise.Results: As outcomes, separate simple algorithms are presented for the treatment of predominant comedonal, predominant papulopustular and nodular/conglobate acne. Patients with predominant comedonal acne should initially be treated with a topical retinoid, azelaic acid or salicylic acid. Fixed combination topicals are recommended for patients with predominant papulopustular acne with treatment tailored according to the severity of disease. Treatment recommendations for nodular/conglobate acne include oral isotretinoin or fixed combinations plus oral antibiotics in men, and these options may be supplemented with oral anti‐androgenic hormonal therapy in women. Further decisions regarding treatment responses should be evaluated 8 weeks after treatment initiation in patients with predominant comedonal or papulopustular acne and 12 weeks after in those with nodular/conglobate acne. Maintenance therapy with a topical retinoid or azelaic acid should be commenced once a patient is clear or almost clear of their acne to prevent the disease from recurring. The principal explanations for lack of treatment response fall into 5 main categories: disease progression, non‐drug‐related reasons, drug‐related reasons, poor adherence, and adverse events.Conclusion: This practical guide provides dermatologists with treatment algorithms adapted to different clinical features of acne which are simple and easy to use in daily clinical practice. The checklists to establish the causes for a lack of treatment response and subsequent action to take will facilitate successful acne management.